Analyst Consensus ?
ConsensusHold29 ratings
Bullish13.5%
Neutral1758.6%
Bearish1137.9%
Campbell Soup Company · CPB · FY2025 Q1 · Calendar Q4 2024
Campbell reaffirms guidance as Sovos and Rao’s support growth
The supplied analysis supports a constructive but qualified view: acquisition contribution, Rao’s momentum, leadership-brand share gains, and cost savings are supporting Campbell’s trajectory, while organic sales softness and snack-margin pressure temper the case for durable growth.
Reported Before market openNASDAQConsumer Defensive
$5.64B market cap
80quality score
Earnings scorecard
Reported versus consensus
Reported EPS
—
Consensus $0.88
EPS surprise
—
Reported versus consensus
Reported revenue
—
Consensus $2.80B
Revenue surprise
—
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-6.2%
Event window
SPY move
+0.6%
Same window
Abnormal move
-6.9%
Stock minus SPY
Volume
2.5×
Versus trailing sessions
Subsequent drift
-2.2%
Up to 20 sessions
CPBSPY benchmark
Ask FN2 about CPB FY2025 Q1
Transcript, numbers and history already loaded
What drove CPB's -6.2% move after FY2025 Q1 earnings?What changed in CPB's guidance and outlook in FY2025 Q1?Give me the bull and bear case for CPB after FY2025 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior quarter, the current analysis shifts emphasis from the initial Sovos integration and FY25 setup to early execution: Sovos remained a major sales contributor, Rao’s expanded its growth pipeline, cost savings were realized, and management reaffirmed guidance. The CEO transition and holiday-season investment also became more prominent.
Guidance delta
Management maintained full-year guidance and expected sequential top-line momentum in Q2.
Key takeaways
- Reported sales growth was driven by the Sovos acquisition, while organic sales were slightly down.
- Rao’s and other leadership brands delivered strong dollar and share gains.
- Cost savings supported margin expansion, with $30 million delivered early.
- Management highlighted holiday marketing, snack innovation, and continued Sovos integration.
- The outlook still faces pressure from snack competition, consumer conditions, and input costs.
Management priorities
- Continue Sovos Brands integration and accelerate cost savings.
- Expand Rao’s, including Alfredo and white-truffle marinara offerings.
- Launch snack innovations including Pop’ums and Bites.
- Increase holiday-season marketing and promotional activity.
- Maintain dividend growth and share repurchases.
Follow CPB with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$19.37Previous close
$18Low
$33.8Average
$59High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 9, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | In Line | In Line | Maintain | Sep 14, 2026 |
| DA Davidson | Neutral | Neutral | Maintain | Sep 8, 2026 |
| UBS | Sell | Sell | Maintain | Sep 4, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Sep 4, 2026 |
| Jefferies | Hold | Hold | Maintain | Sep 4, 2026 |
| Barclays | Underweight | Underweight | Maintain | Sep 4, 2026 |
| TD Cowen | Hold | Hold | Maintain | Aug 19, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Aug 18, 2026 |
| Stifel | Hold | Hold | Maintain | Jul 22, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Jun 9, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jun 5, 2026 |
| Bernstein | Underperform | Market Perform | Downgrade | Jun 3, 2026 |
| Stephens & Co. | Equal Weight | Overweight | Downgrade | Jun 1, 2026 |
| BNP Paribas | Underperform | Underperform | Maintain | Apr 9, 2026 |
| Wells Fargo | Underweight | Underweight | Maintain | Apr 8, 2026 |
| Deutsche Bank | Hold | Hold | Maintain | Mar 30, 2026 |
| Piper Sandler | Neutral | Overweight | Downgrade | Aug 7, 2025 |
| Citigroup | Sell | Sell | Maintain | Jun 3, 2025 |
| Argus Research | Buy | Hold | Upgrade | Sep 20, 2024 |
| Goldman Sachs | Sell | Sell | Maintain | Aug 23, 2023 |
| Credit Suisse | Neutral | Neutral | Maintain | Mar 9, 2023 |
| Exane BNP Paribas | Underperform | Underperform | Maintain | Nov 15, 2022 |
| R5 Capital | Hold | Buy | Downgrade | Mar 14, 2022 |
| Piper Jaffray | Neutral | Underweight | Upgrade | Sep 4, 2019 |
| Bank of America | Underperform | Underperform | Maintain | Sep 3, 2019 |
| Stifel Nicolaus | Hold | Hold | Maintain | May 21, 2018 |
| Argus | Hold | Buy | Downgrade | May 5, 2018 |
| PiperJaffray | Underweight | Neutral | Downgrade | Mar 1, 2018 |
| CLSA | Perform | Perform | Maintain | Sep 12, 2016 |
Named analyst price targets
Upside is calculated against the persisted previous close $19.37. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Evercore ISI | Analyst unavailable | $21 | $21 | +8.4% | Sep 14, 2026 |
| RBC Capital | Analyst unavailable | $19 | $21.27 | -1.9% | Sep 4, 2026 |
| Barclays | Analyst unavailable | $18 | $22.12 | -7.1% | Sep 4, 2026 |
| Jefferies | Analyst unavailable | $20 | $22.12 | +3.3% | Sep 3, 2026 |
| Evercore ISI | Analyst unavailable | $22 | $23.39 | +13.6% | Aug 31, 2026 |
| Stephens | Analyst unavailable | $20 | $23.28 | +3.3% | Aug 28, 2026 |
| UBS | Analyst unavailable | $18 | $23.81 | -7.1% | Aug 20, 2026 |
| Coker Palmer | Thomas Palmer | $22 | $22.68 | +13.6% | Aug 18, 2026 |
| RBC Capital | Analyst unavailable | $21 | $21.49 | +8.4% | Jun 9, 2026 |
| UBS | Analyst unavailable | $17 | $21.49 | -12.2% | Jun 9, 2026 |
| Bernstein | Alexia Howard | $18 | $21.49 | -7.1% | Jun 9, 2026 |
| Barclays | Andrew Lazar | $19 | $21.68 | -1.9% | Jun 8, 2026 |
| Morgan Stanley | Analyst unavailable | $21 | $21.55 | +8.4% | Jun 5, 2026 |
| Bernstein | Analyst unavailable | $19 | $20.99 | -1.9% | Jun 3, 2026 |
| UBS | Analyst unavailable | $19 | $21.26 | -1.9% | Jun 2, 2026 |
| Stephens | Analyst unavailable | $21 | $21.11 | +8.4% | Jun 1, 2026 |
| D.A. Davidson | Brian Holland | $20 | $20.47 | +3.3% | May 22, 2026 |
| Morgan Stanley | Analyst unavailable | $23 | $20.82 | +18.7% | Apr 23, 2026 |
| Stifel Nicolaus | Matthew Smith | $20 | $21.26 | +3.3% | Apr 21, 2026 |
| Barclays | Andrew Lazar | $21 | $19.78 | +8.4% | Apr 14, 2026 |
| BNP Paribas | Analyst unavailable | $19 | $20.79 | -1.9% | Apr 9, 2026 |
| Wells Fargo | Analyst unavailable | $18 | $20.69 | -7.1% | Apr 8, 2026 |
| UBS | Analyst unavailable | $24 | $22.15 | +23.9% | Mar 12, 2026 |
| UBS | Analyst unavailable | $23 | $22.1 | +18.7% | Mar 12, 2026 |
| Barclays | Andrew Lazar | $23 | $22.94 | +18.7% | Mar 12, 2026 |
| Piper Sandler | Analyst unavailable | $28 | $25.29 | +44.6% | Mar 9, 2026 |
| Jefferies | Scott Marks | $26 | $26.95 | +34.2% | Mar 2, 2026 |
| Barclays | Analyst unavailable | $27 | $26.1 | +39.4% | Jan 16, 2026 |
| Morgan Stanley | Megan Clapp | $28 | $26.9 | +44.6% | Jan 16, 2026 |
| RBC Capital | Nik Modi | $30 | $28.17 | +54.9% | Dec 10, 2025 |
| UBS | Analyst unavailable | $26 | $28.47 | +34.2% | Dec 10, 2025 |
| Stifel Nicolaus | Matthew Smith | $30 | $28.47 | +54.9% | Dec 10, 2025 |
| Bernstein | Analyst unavailable | $33 | $28.47 | +70.4% | Dec 10, 2025 |
| Wells Fargo | Chris Carey | $30 | $28.47 | +54.9% | Dec 10, 2025 |
| Stifel Nicolaus | Matthew Smith | $34 | $29.04 | +75.5% | Dec 9, 2025 |
| Stephens | Analyst unavailable | $38 | $29.6 | +96.2% | Dec 8, 2025 |
| Morgan Stanley | Megan Alexander Clapp | $30 | $29.38 | +54.9% | Dec 5, 2025 |
| UBS | Peter Grom | $28 | $29.84 | +44.6% | Dec 4, 2025 |
| D.A. Davidson | Brian Holland | $30 | $31.1 | +54.9% | Nov 17, 2025 |
| UBS | Analyst unavailable | $30 | $31.93 | +54.9% | Aug 29, 2025 |
| Coker Palmer | Thomas Palmer | $33 | $35.48 | +70.4% | May 19, 2025 |
| Bernstein | Alexia Howard | $47 | $39.82 | +142.6% | Apr 3, 2025 |
| Wells Fargo | Analyst unavailable | $40 | $39.79 | +106.5% | Mar 6, 2025 |
| Barclays | Analyst unavailable | $40 | $39.18 | +106.5% | Mar 5, 2025 |
| Piper Sandler | Analyst unavailable | $45 | $39.18 | +132.3% | Mar 5, 2025 |
| Piper Sandler | Michael Lavery | $56 | $42.59 | +189.1% | Dec 5, 2024 |
| Evercore ISI | David Palmer | $48 | $42.82 | +147.8% | Dec 5, 2024 |
| Coker Palmer | Thomas Palmer | $44 | $49.13 | +127.2% | Nov 18, 2024 |
| Bernstein | Alexia Howard | $58 | $47.35 | +199.4% | Oct 7, 2024 |
| Argus Research | Taylor Conrad | $59 | $51.42 | +204.6% | Sep 20, 2024 |
| RBC Capital | Nik Modi | $51 | $49.78 | +163.3% | Sep 13, 2024 |
| Stifel Nicolaus | Matthew Smith | $50 | $50.11 | +158.1% | Sep 11, 2024 |
| Wells Fargo | John Baumgartner | $51 | $50.09 | +163.3% | Sep 11, 2024 |
| Wells Fargo | Chris Carey | $49 | $49.25 | +153.0% | Aug 30, 2024 |
| Goldman Sachs | Ken Goldman | $52 | $45.63 | +168.5% | Jun 26, 2024 |
| Wells Fargo | John Baumgartner | $47 | $43.53 | +142.6% | Jun 7, 2024 |
| RBC Capital | Nik Modi | $47 | $43.42 | +142.6% | May 30, 2024 |
| Coker Palmer | Thomas Palmer | $42 | $46.29 | +116.8% | May 22, 2024 |
| Deutsche Bank | Steve Powers | $48 | $46.46 | +147.8% | May 20, 2024 |
| Bernstein | Alexia Howard | $46 | $46.01 | +137.5% | May 15, 2024 |
| Evercore ISI | David Palmer | $49 | $42.81 | +153.0% | Mar 13, 2024 |
| Stifel Nicolaus | Matthew Smith | $45 | $43.01 | +132.3% | Mar 12, 2024 |
| Piper Sandler | Michael Lavery | $47 | $43.39 | +142.6% | Dec 7, 2023 |
| J.P. Morgan | Ken Goldman | $47 | $41.96 | +142.6% | Aug 31, 2023 |
| RBC Capital | Nik Modi | $50 | $52.68 | +158.1% | Mar 9, 2023 |
| Morgan Stanley | Analyst unavailable | $57 | $56.22 | +194.3% | Dec 20, 2022 |
| Deutsche Bank | Analyst unavailable | $53 | $56.49 | +173.6% | Dec 8, 2022 |
| Piper Sandler | Analyst unavailable | $55 | $56.57 | +183.9% | Dec 8, 2022 |
| Credit Suisse | Analyst unavailable | $54 | $56.18 | +178.8% | Dec 8, 2022 |
| Morgan Stanley | Peter Galbo | $46 | $55.75 | +137.5% | Dec 7, 2022 |
| BNP Paribas | Analyst unavailable | $48 | $48.34 | +147.8% | Nov 15, 2022 |
| Morgan Stanley | Pamela Kaufman | $48 | $48.78 | +147.8% | Sep 21, 2022 |
| Credit Suisse | Robert Moskow | $52 | $48.87 | +168.5% | Sep 6, 2022 |
| Piper Sandler | Analyst unavailable | $46 | $50.38 | +137.5% | Sep 2, 2022 |
| Deutsche Bank | Analyst unavailable | $50 | $51.17 | +158.1% | Aug 22, 2022 |
| Deutsche Bank | Analyst unavailable | $49 | $47.62 | +153.0% | Jun 9, 2022 |
| Stifel Nicolaus | Analyst unavailable | $48 | $47.31 | +147.8% | Jun 9, 2022 |
| Deutsche Bank | Analyst unavailable | $47 | $46.62 | +142.6% | Jun 1, 2022 |
| R5 Capital | Scott Mushkin | $44.51 | $42.81 | +129.8% | Mar 14, 2022 |
| Piper Sandler | Michael Lavery | $43 | $39.71 | +122.0% | Nov 2, 2021 |
| Barclays | Andrew Lazar | $43 | $39.96 | +122.0% | Oct 21, 2021 |
| Bank of America Securities | Bryan Spillane | $42 | $41.74 | +116.8% | Sep 2, 2021 |
| Stifel Nicolaus | Christopher Growe | $44 | $41.52 | +127.2% | Sep 1, 2021 |
Track every rating change on CPB the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationCampbell Soup Company (CPB) is a leading international producer and marketer of a wide variety of food and beverage products. The enterprise conducts its business through two main operational divisions: Meals & Beverages and Snacks. The Meals & Beverages segment serves both retail and food service industries throughout the United States and Canada. Its extensive product range includes classic Campbell's condensed and ready-to-enjoy soups; Swanson brand broths and stocks; Pacific Foods' line of broths, soups, and non-dairy beverages; Prego pasta sauces; Pace brand Mexican sauces; Campbell's gravies, pasta dishes, beans, and dinner sauces; Swanson canned poultry; Plum organic baby food and snacks; V8 juices and drinks; and Campbell's tomato juice. The Snacks division primarily targets the retail sector, with a significant presence in Latin America.…
Historical context
All CPB earningsConsumer Defensive peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| PEP PepsiCo, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +3.7% | PepsiCo: International Growth Offsets U.S. Soft-Drink and Margin Pressure |
| STZ Constellation Brands, Inc. | FY2027 Q2 · Calendar Q4 2026 | +5.4% | +2.4% | Constellation Brands beats expectations and maintains FY27 EPS guidance |
| LW Lamb Weston Holdings, Inc. | FY2027 Q1 · Calendar Q4 2026 | +27.8% | +7.5% | Lamb Weston raises FY2027 outlook as North America volume growth continues |
| MKC McCormick & Company, Incorporated | FY2026 Q3 · Calendar Q4 2026 | +13.9% | -4.9% | McCormick reports strong Q3 growth while U.S. volumes remain soft |
| CAG Conagra Brands, Inc. | FY2027 Q1 · Calendar Q3 2026 | +44.4% | -4.9% | Conagra maintains outlook while increasing brand investment and simplifying SKUs |
| COST Costco Wholesale Corporation | FY2026 Q4 · Calendar Q3 2026 | +3.2% | +2.9% | Costco’s growth broadens as warehouses and digital sales accelerate |
Latest beats and misses
Who reports nextBeat on EPS
Get the CPB recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-11-20T00:01:49.813283+00:00
- Polygon adjusted daily market bars · 2026-10-09T06:50:42.911730+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-09T06:50:42.909010+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-09. For educational purposes only; not investment advice.